AAVantgarde Bio
Milano
About AAVantgarde Bio
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders. Its platform addresses a major limitation in traditional AAV (adeno-associated virus) gene delivery by enabling the packaging and delivery of large genes that exceed the usual vector capacity. The company’s two lead programs are AAVB-039, targeting Stargardt disease caused by ABCA4 mutations, and AAVB-081, for Usher syndrome type 1B (Usher 1B), affecting vision and hearing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $206.3M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2025)
- Website: aavantgarde.com
- Phone: +39 329-552-4297
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aavantgarde-bio-30431 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.